TABLE 1.
Potential drugs targeting the darkturquoise module.
| Compound | Enrichment score a | Specificity b | Cell line c |
|---|---|---|---|
| Anisomycin | −0.99 | 0 | MCF7, PC3, and HL60 |
| MG-262 | −0.98 | 0 | MCF7 and PC3 |
| Cicloheximide | −0.93 | 0.0148 | MCF7, PC3, and HL60 |
| Ikarugamycin | −0.906 | 0.0076 | MCF7 |
| 5279552 | −0.872 | 0.0238 | MCF7 |
| Isoflupredone | −0.864 | 0.125 | MCF7, PC3, and HL60 |
| Fasudil | −0.854 | 0.0056 | MCF7 and PC3 |
| Lomustine | −0.831 | 0.0141 | MCF7 and PC3 |
| Sulmazole | −0.823 | 0.0396 | MCF7, PC3, and HL60 |
| Lycorine | −0.808 | 0.0267 | MCF7, PC3, and HL60 |
a
Enrichment scores indicate the similarity of the gene expression of OA, module, and the gene signature of the compounds. Negative scores represent the opposite relationships between them.
b
Specificity measures the uniqueness of the connection between a perturbagen and the signature of interest. Small values of specificity indicate high uniqueness between signatures and gene modules.
c
Cell lines involved in the assessments.